PhXA41
DrugOne drop in the affected eye once daily for six months.
NCT Number: NCT00751127
PhXA41 is not inferior to timolol
Looking for future studies?
Notify Me40 year and older
All sexes
Interventional
Phase 3
Pfizer Investigational Site, La Jolla, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
One drop in the affected eye once daily for six months.
One drop in the affected eye twice daily for six months.
Time frame: 6 mos
Time frame: 6 mos
Pfizer
Industry
A 6-month, Randomized, Double-masked Comparison of Latanoprost (PhXA41) With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension. A Multi-centre Study in the United States.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04911387
Exfoliation Syndrome, Eye Diseases
Stockholm, Sweden
View Trial DetailsNCT02628223
Eye Diseases, Glaucoma
Wilmington, Delaware, United States
View Trial DetailsNCT06689696
Eye Diseases, GLAUCOMA 1, OPEN ANGLE, D (Disorder)
Fullerton, California, United States
View Trial DetailsNCT05181046
Eye Diseases, Glaucoma
Madurai, India
View Trial Details